SCHEMBL13664161

SCHEMBL13664161

Cc1ccc(C(=O)c2nn(-c3ccc(Cl)cc3)c(N)c2C#N)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.51
GAA P10253 4/20 0.51
TDP1 Q9NUW8 2/20 0.51
POLB P06746 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ALDH1A1 P00352 4/20 0.50
LMNA P02545 4/20 0.50
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
HPGD P15428 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
KDM4E B2RXH2 4/20 0.46
NPSR1 Q6W5P4 3/20 0.46
RXFP1 Q9HBX9 1/20 0.46
PPP1CA P62136 1/20 0.40
HTT P42858 2/20 0.40
CNR1 P21554 1/20 0.39
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
PTGS2 P35354 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13664173 0.94 MAPT (0.55) MAPTGAATDP1POLBL3MBTL1
SCHEMBL13664223 0.91 MAPT (0.52) MAPTGAATDP1POLBL3MBTL1
SCHEMBL13664182 0.89 MAPT (0.51) MAPTGAATDP1POLBL3MBTL1
SCHEMBL13664163 0.89 MAPT (0.51) MAPTGAATDP1POLBL3MBTL1
SCHEMBL13664224 0.89 MAPT (0.51) MAPTGAATDP1POLBL3MBTL1
SCHEMBL13664183 0.89 KMT2A (0.50) MAPTGAATDP1POLBL3MBTL1
SCHEMBL13664170 0.88 MAPT (0.50) MAPTGAATDP1POLBL3MBTL1
SCHEMBL13664162 0.88 MEN1 (0.51) MAPTGAATDP1ALDH1A1LMNA
SCHEMBL13664203 0.88 MAPT (0.50) MAPTGAATDP1POLBL3MBTL1
SCHEMBL13664177 0.88 MAPT (0.50) MAPTGAATDP1POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists GIPR, GPR119, GLP1R MAPT 4701/4885GAA 2005/4885TDP1 4748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.